Lukas Reiter

Lukas Reiter

Auto-generated profile, based on publicly available information

Lukas Reiter

Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
RBRoland Bruderer
Roland Bruderer
OBOliver M. Bernhardt
Oliver M. Bernhardt
TGTejas Gandhi
Tejas Gandhi
YXYue Xuan
Yue Xuan
JSJulia Sondermann
Julia Sondermann
LRLukas Reiter
Lukas Reiter
Comprehensive, reproducible and precise analysis of large sample cohorts is one of the key objectives of quantitative proteomics. Here, we present an implementation of data-independent acquisition using its parallel acquisition nature that surpasses the limitation of serial MS2 acquisition of data-dependent acquisition on a quadrupole ultra-high field Orbitrap mass spectrometer. In deep single shot data-independent acquisition, we identified and quantified 6,383 proteins in human cell lines using 2-or-more peptides/protein and over 7100 proteins when including the 717 proteins that were identified on the basis of a single peptide sequence. 7739 proteins were identified in mouse tissues using 2-or-more peptides/protein and 8121 when including the 382 proteins that were identified based on a single peptide sequence. Missing values for proteins were within 0.3 to 2.1% and median coefficients of variation of 4.7 to 6.2% among technical triplicates. In very complex mixtures, we could quantify 10,780 proteins and 12,192 proteins when including the 1412 proteins that were identified based on a single peptide sequence. Using this optimized DIA, we investigated large-protein networks before and after the critical period for whisker experience-induced synaptic strength in the murine somatosensory cortex 1-barrel field. This work shows that parallel mass spectrometry enables proteome profiling for discovery with high coverage, reproducibility, precision and scalability.

7 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DBDorte B. Bekker-Jensen
Dorte B. Bekker-Jensen
OBOliver M. Bernhardt
Oliver M. Bernhardt
AHAlexander Hogrebe
Alexander Hogrebe
AMAna Martinez-Val
Ana Martinez-Val
LVLynn Verbeke
Lynn Verbeke
JOJesper V. Olsen
Jesper V. Olsen
Quantitative phosphoproteomics has transformed investigations of cell signaling, but it remains challenging to scale the technology for high-throughput analyses. Here we report a rapid and reproducible approach to analyze hundreds of phosphoproteomes using data-independent acquisition (DIA) with an accurate site localization score incorporated into Spectronaut. DIA-based phosphoproteomics achieves an order of magnitude broader dynamic range, higher reproducibility of identification, and improved sensitivity and accuracy of quantification compared to state-of-the-art data-dependent acquisition (DDA)-based phosphoproteomics. Notably, direct DIA without the need of spectral libraries performs close to analyses using project-specific libraries, quantifying > 20,000 phosphopeptides in 15 min single-shot LC-MS analysis per condition. Adaptation of a 3D multiple regression model-based algorithm enables global determination of phosphorylation site stoichiometry in DIA. Scalability of the DIA approach is demonstrated by systematically analyzing the effects of thirty kinase inhibitors in context of epidermal growth factor (EGF) signaling showing that specific protein kinases mediate EGF-dependent phospho-regulation.

21 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
IPIlaria Piazza
Ilaria Piazza
NBNigel Beaton
Nigel Beaton
RBRoland Bruderer
Roland Bruderer
TKThomas Knobloch
Thomas Knobloch
CBCrystel Barbisan
Crystel Barbisan
LRLukas Reiter
Lukas Reiter
Chemoproteomics is a key technology to characterize the mode of action of drugs, as it directly identifies the protein targets of bioactive compounds and aids in the development of optimized small-molecule compounds. Current approaches cannot identify the protein targets of a compound and also detect the interaction surfaces between ligands and protein targets without prior labeling or modification. To address this limitation, we here develop LiP-Quant, a drug target deconvolution pipeline based on limited proteolysis coupled with mass spectrometry that works across species, including in human cells. We use machine learning to discern features indicative of drug binding and integrate them into a single score to identify protein targets of small molecules and approximate their binding sites. We demonstrate drug target identification across compound classes, including drugs targeting kinases, phosphatases and membrane proteins. LiP-Quant estimates the half maximal effective concentration of compound binding sites in whole cell lysates, correctly discriminating drug binding to homologous proteins and identifying the so far unknown targets of a fungicide research compound.

1 June 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
RBRoland Bruderer
Roland Bruderer
JMJan Muntel
Jan Muntel
SMSebastian Müller
Sebastian Müller
OBOliver M. Bernhardt
Oliver M. Bernhardt
TGTejas Gandhi
Tejas Gandhi
LRLukas Reiter
Lukas Reiter
Comprehensive, high throughput analysis of the plasma proteome has the potential to enable holistic analysis of the health state of an individual. Based on our own experience and the evaluation of recent large-scale plasma mass spectrometry (MS) based proteomic studies, we identified two outstanding challenges: slow and delicate nano-flow liquid chromatography (LC) and irreproducibility of identification of data-dependent acquisition (DDA). We determined an optimal solution reducing these limitations with robust capillary-flow data-independent acquisition (DIA) MS. This platform can measure 31 plasma proteomes per day. Using this setup, we acquired a large-scale plasma study of the diet, obesity and genes dietary (DiOGenes) comprising 1508 samples. Proving the robustness, the complete acquisition was achieved on a single analytical column. Totally, 565 proteins (459 identified with two or more peptide sequences) were profiled with 74% data set completeness. On average 408 proteins (5246 peptides) were identified per acquisition (319 proteins in 90% of all acquisitions). The workflow reproducibility was assessed using 34 quality control pools acquired at regular intervals, resulting in 92% data set completeness with CVs for protein measurements of 10.9%. The profiles of 20 apolipoproteins could be profiled revealing distinct changes. The weight loss and weight maintenance resulted in sustained effects on low-grade inflammation, as well as steroid hormone and lipid metabolism, indicating beneficial effects. Comparison to other large-scale plasma weight loss studies demonstrated high robustness and quality of biomarker candidates identified. Tracking of nonenzymatic glycation indicated a delayed, slight reduction of glycation in the weight maintenance phase. Using stable-isotope-references, we could directly and absolutely quantify 60 proteins in the DIA. In conclusion, we present herein the first large-scale plasma DIA study and one of the largest clinical research proteomic studies to date. Application of this fast and robust workflow has great potential to advance biomarker discovery in plasma. Graphical Abstract Highlights Robust capillary-flow DIA was established at 31 clinical samples per day. 1508 samples of dietary intervention study DiOGenes were measured on a single column. Comprehensive biological reactions to weight loss and maintenance were observed. Comparison to independent studies shows high reproducibility of potential biomarkers.

29 August 2019 in Molecular Omics
Verified
Journal Article
Open access
PDF file
JMJan Muntel
Jan Muntel
TGTejas Gandhi
Tejas Gandhi
LVLynn Verbeke
Lynn Verbeke
OBOliver M. Bernhardt
Oliver M. Bernhardt
TTTobias Treiber
Tobias Treiber
LRLukas Reiter
Lukas Reiter
Comprehensive proteome quantification is crucial for a better understanding of underlying mechanisms of diseases. Liquid chromatography mass spectrometry (LC-MS) has become the method of choice for comprehensive proteome quantification due to its power and versatility. Even though great advances have been made in recent years, full proteome coverage for complex samples remains challenging due to the high dynamic range of protein expression. Additionally, when studying disease regulatory proteins, biomarkers or potential drug targets are often low abundant, such as for instance kinases and transcription factors. Here, we show that with improvements in chromatography and data analysis the single shot proteome coverage can go beyond 10 000 proteins in human tissue. In a testis cancer study, we quantified 11 200 proteins using data independent acquisition (DIA). This depth was achieved with a false discovery rate of 1% which was experimentally validated using a two species test. We introduce the concept of hybrid libraries which combines the strength of direct searching of DIA data as well as the use of large project-specific or published DDA data sets. Remarkably deep proteome coverage is possible using hybrid libraries without the additional burden of creating a project-specific library. Within the testis cancer set, we found a large proportion of proteins in an altered expression (in total: 3351; 1453 increased in cancer). Many of these proteins could be linked to the hallmarks of cancer. For example, the complement system was downregulated which helps to evade the immune response and chromosomal replication was upregulated indicating a dysregulated cell cycle.

6 February 2019 in Journal of Proteome Research
Verified
Journal Article
Closed access
JMJan Muntel
Jan Muntel
JKJoanna Kirkpatrick
Joanna Kirkpatrick
RBRoland Bruderer
Roland Bruderer
THTing Huang
Ting Huang
OVOlga Vitek
Olga Vitek
LRLukas Reiter
Lukas Reiter